ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
Start Date
9/28/2018
Completion Date
1/1/2030
Summary
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Detailed Description
This is a prospective, multi-center, single-arm study to evaluate the safety and efficacy of BBB disruption using the ExAblate Model 4000 Type 2.0 (220 kHz) system. Patients with diagnosis of Probable Alzheimer's Disease may qualify for a clinical trial to have three serial ExAblate BBB disruption procedures in specific areas in the brain. This study will be conducted at up to 8 sites in the United States and will enroll up to 30 patients.
Eligibility Criteria
Age Range: 50 years to 85 years
Interventions
Blood Brain Barrier (BBB) Disruption
Conditions
Locations
Delray Medical Center & Florida Atlantic University
Delray Beach, Florida 33484
United States
Broward Health Medical Center & The University of Florida
Fort Lauderdale, Florida 33316
United States
University of Florida Health Shands
Gainesville, Florida 32608
United States
Baptist Health South Florida & Florida International University
Miami, Florida 33176
United States
Advent Health
Orlando, Florida 34747
United States
Tampa General Hospital
Tampa, Florida 33612
United States
Weill Cornell Medicine
New York, New York 10065
United States
The Ohio State University -Wexner Medical Center
Columbus, Ohio 43210
United States
University of Texas Southwestern Medical Center
Dallas, Texas 75390
United States
West Virginia University Rockefeller Neuroscience Center
Morgantown, West Virginia 26506
United States